COMPANY

Reprise Biomedical

HQ: Plymouth, MN source · reprisebio.com ↗

Keywords: medical device medical devices Diabetic Foot Ulcers Chronic Wounds Diabetic Foot Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer) Venous Leg Ulcers Pressure Ulcers Surgical Wound Dehiscence Undermined and Tunneling Wounds Miro3D Wound Matrix Acellular Porcine-Derived Wound Matrix

Location: Plymouth, MN · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $9.25M (Form D filed May 21, 2026; amended Jul 1, 2026). SEC Form D 0001782236-26-000001 (May 21, 2026)
Evidence (1 event)
- May 21, 2026 · SEC Form D 0001782236-26-000001
  Name of Issuer: Reprise Biomedical, Inc.; CIK: 1782236; Address: Plymouth, MN; Submission type: D; Filing date: 2026-05-21; Industry Group: Biotechnology; Date of First Sale: 2026-05-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 1450000; Federal exemptions: 06b || Name of Issuer: Reprise Biomedical, Inc.; CIK: 1782236; Address: Plymouth, MN; Submission type: D/A; Filing date: 2026-07-01; Industry Group: Biotechnology; Date of First Sale: 2026-05-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 9246100; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 15, 2026 Trial start Not phased (device or behavioral study): Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers source ↗
Nov 1, 2024 Trial start Not phased (device or behavioral study): Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing source ↗
Feb 29, 2024 Trial start Not phased (device or behavioral study): Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care source ↗

Upcoming milestones

2027-03 (ESTIMATED) · Not phased · Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers · NCT07632001

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07632001	Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers	Not phased (device or behavioral study)	Recruiting	Jun 15, 2026	2027-03 (estimated)
NCT06939686	Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing	Not phased (device or behavioral study)	Recruiting	Nov 1, 2024	Jul 31, 2026 (estimated)
NCT06939673	Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care	Not phased (device or behavioral study)	Recruiting	Feb 29, 2024	Dec 31, 2025 (estimated)